C-Met Mutated Non-small Cell Lung Cancer (NSCLC) Pipeline Landscape Report 2021 - ResearchAndMarkets.com

The "C-Met Mutated Non-small Cell Lung Cancer (NSCLC) - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

This "C-Met Mutated Non-small Cell Lung Cancer (NSCLC) - Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in C-Met Mutated Non-small Cell Lung Cancer (NSCLC) pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) R&D. The therapies under development are focused on novel approaches to treat/improve C-Met Mutated Non-Small Cell Lung Cancer (NSCLC).

C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Emerging Drugs Chapters

This segment of the C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Emerging Drugs

EGF-816 (Nazartinib): Novartis Oncology

Novarti's lead drug candidate, EGF-816 (Nazartinib), is small molecule in combination with INC280 is in development for the treatment of non-small cell lung cancer. Clinical trials data demonstrated that EGF-816 (Nazartinib) for the treatment of C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) has beneficial effects. The drug is a new molecule which is an epidermal growth factor receptor antagonist that blocks the function of protein EGFR.

APL 101 (Bozitinib): Appolomics Inc.

Apollomics drug APL 101 (Bozitinib) is an orally administered small molecule currently being evaluated for the treatment of C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) and has demonstrated good safety and efficacy profile in phase II trials. APL 101 (Bozitinib) is an anti-neoplastics which inhibits the C-met protein.

Major Players in C-Met Mutated Non-small Cell Lung Cancer (NSCLC)

There are approx. 5+ key companies which are developing the therapies for C-Met Mutated Non-small Cell Lung Cancer (NSCLC). The companies which have their C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) drug candidates in the mid to advanced stage, i.e. phase III include, Novartis Oncology and others.

C-Met Mutated Non-small Cell Lung Cancer (NSCLC): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) drugs.

Key Questions Answered

• How many companies are developing C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) drugs?
• How many C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of C-Met Mutated Non-Small Cell Lung Cancer (NSCLC)?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Novartis
• Apollomics Inc.
• Abbvie
• Janssen Research and Development

Key Products

• EGF-816 (Nazartinib)
• APL 101 (Bozitinib)
• Telisotuzumab Vedotin
• JNJ-6118637

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/oyf22u

View source version on businesswire.com: https://www.businesswire.com/news/home/20210929005590/en/